BACKGROUND: The highly vascular nature of renal cell carcinoma (RCC) suggests that angiogenesis inhibition may be therapeutic for patients with this disease. Thalidomide inhibits basic fibroblast growth factor and vascular endothelial growth factor (VEGF)-induced angiogenesis. METHODS: In a pilot study, we evaluated the safety and efficacy of escalating doses of thalidomide in patients with progressive metastatic RCC (mRCC), measurable disease, and good organ function. Patients received oral thalidomide starting at 200 mg per day and increasing by 100-200 mg per day weekly until a target dose of 1200 mg per day was reached. Study endpoints were objective tumor response and toxicity. RESULTS: Of the 20 patients enrolled, 19 were evaluable for response. Eighteen achieved the target dose. The most common, but reversible, toxicities were constipation, somnolence, and fatigue. Peripheral neuropathy was seen after prolonged therapy, necessitating dose reduction. Two patients achieved a partial response and nine had stable disease for a median of 14 months (range, 3-17 months). Median time to progression was 4.7 months (range, 0.7-31.3 months). Fifteen patients died (median survival, 18.1 months; 95% lower confidence bound 10.7). Survival was significantly longer in patients with higher hemoglobin level and longer time from first metastasis to start of thalidomide, but significantly shorter in patients with multiple organ involvement and previous treatments. CONCLUSIONS: Thalidomide at this dose is associated with manageable acute toxicities but long-term dose-limiting neuropathy. Objective responses are rare in patients with mRCC and are characterized by delay in achieving maximum tumor reduction. Prolonged stable disease is seen in some patients, but the benefit of thalidomide, as well as other angiogenesis inhibitors, in that setting needs to be studied in controlled, randomized trials. Copyright 2002 American Cancer Society.DOI 10.1002/cncr.10740
BACKGROUND: The highly vascular nature of renal cell carcinoma (RCC) suggests that angiogenesis inhibition may be therapeutic for patients with this disease. Thalidomide inhibits basic fibroblast growth factor and vascular endothelial growth factor (VEGF)-induced angiogenesis. METHODS: In a pilot study, we evaluated the safety and efficacy of escalating doses of thalidomide in patients with progressive metastatic RCC (mRCC), measurable disease, and good organ function. Patients received oral thalidomide starting at 200 mg per day and increasing by 100-200 mg per day weekly until a target dose of 1200 mg per day was reached. Study endpoints were objective tumor response and toxicity. RESULTS: Of the 20 patients enrolled, 19 were evaluable for response. Eighteen achieved the target dose. The most common, but reversible, toxicities were constipation, somnolence, and fatigue. Peripheral neuropathy was seen after prolonged therapy, necessitating dose reduction. Two patients achieved a partial response and nine had stable disease for a median of 14 months (range, 3-17 months). Median time to progression was 4.7 months (range, 0.7-31.3 months). Fifteen patients died (median survival, 18.1 months; 95% lower confidence bound 10.7). Survival was significantly longer in patients with higher hemoglobin level and longer time from first metastasis to start of thalidomide, but significantly shorter in patients with multiple organ involvement and previous treatments. CONCLUSIONS:Thalidomide at this dose is associated with manageable acute toxicities but long-term dose-limiting neuropathy. Objective responses are rare in patients with mRCC and are characterized by delay in achieving maximum tumor reduction. Prolonged stable disease is seen in some patients, but the benefit of thalidomide, as well as other angiogenesis inhibitors, in that setting needs to be studied in controlled, randomized trials. Copyright 2002 American Cancer Society.DOI 10.1002/cncr.10740
Authors: Thomas Olencki; Sareena Malhi; Tarek Mekhail; Robert Dreicer; Paul Elson; Laura Wood; Ronald M Bukowski Journal: Invest New Drugs Date: 2006-07 Impact factor: 3.850
Authors: Ulka N Vaishampayan; Lance K Heilbrun; Anthony F Shields; Jawana Lawhorn-Crews; Karen Baranowski; Daryn Smith; Lawrence E Flaherty Journal: Invest New Drugs Date: 2006-08-26 Impact factor: 3.850
Authors: Vitaly Margulis; Surena F Matin; Nizar Tannir; Pheroze Tamboli; Yu Shen; Marisa Lozano; David A Swanson; Eric Jonasch; Christopher G Wood Journal: Urology Date: 2008-10-31 Impact factor: 2.649
Authors: Premal H Patel; G Varuni Kondagunta; Lawrence Schwartz; Nicole Ishill; Jennifer Bacik; John DeLuca; Paul Russo; Robert J Motzer Journal: Invest New Drugs Date: 2007-12-27 Impact factor: 3.850
Authors: Anja Kraemer; Stefan Hauser; Young Kim; Marcus Gorschlüter; Stefan C Müller; Peter Brossart; Ingo G H Schmidt-Wolf Journal: Ger Med Sci Date: 2009-06-10